• Policy
• Will AZ/Kolon succeed in challenging COPD combi benefit?
• by Lee, Tak-Sun Jul 5, 2023 05:45am

• Policy
• AZ Capivasertib, designated GIFT No. 8
• by Lee, Hye-Kyung Jul 5, 2023 05:45am

• Opinion
• [Reporter’s View]Kudos to Keytruda for filing 13 reimb apps
• by Eo, Yun-Ho Jul 5, 2023 05:45am

• Company
• Samsung Biologics signs 2 CMO contracts with Pfizer
• by Chon, Seung-Hyun Jul 5, 2023 05:44am

• Company
• Samsung Bioepis launches Humira biosimilar in the US
• by Lee, Seok-Jun Jul 4, 2023 05:37am

• Company
• Celltrion seeks approval for Stelara biosimilar in the US
• by Kim, Jin-Gu Jul 4, 2023 05:37am

• Company
• Discussion on whether Vabysmo benefit is possible
• by Eo, Yun-Ho Jul 4, 2023 05:37am

• Opinion
• [Reporter’s View] Gvn't policies hinder KOR pharma growth
• by Lee, Tak-Sun Jul 4, 2023 05:37am

• Company
• Forxiga expands its benefit through heart failure
• by Jung, Sae-Im Jul 4, 2023 05:36am

• Policy
• Mounjaro, a weight loss effect for DM pts, has been approved
• by Lee, Hye-Kyung Jul 3, 2023 05:47am